Latest Breaking News On - Mybiotics pharma - Page 2 : comparemela.com

Global Gynecology Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

Global Gynecology Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

Swiss pharma firm Ferring, Israel's CytoReason join to battle bowel disease

Newly formed NovoBiome uses AI tech to probe gut-liver link

Newly formed NovoBiome becomes the latest firm to delve into the gut microbiome as it aims to harness Artificial Intelligence (AI) to develop Live Biotherapeutic Products (LBPs) that address liver conditions. NovoBiome, which counts French public research bodies, The National Institute of Agricultural Research (INRAE) and the Bioaster as partners, now look to press ahead with its first LBP drug candidate that targets Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato-Hepatitis (NASH). “The microbiome is a fast growing and disruptive field of research that has the potential to revolutionize the diagnosis, prevention and treatment of liver diseases,”​ says Pierre-Yves Mousset, NovoBiome’s Chief Executive Officer.

Hadassah and MyBiotics to Collaborate for the Discovery of Microbiome-Based Therapy for Improving Cancer Immunotherapy

Share this article REHOVOT and JERUSALEM , Israel, April 6, 2021 /PRNewswire/ MyBiotics Pharma Ltd. http://biomx.com/, a microbiome therapeutics company, and Hadasit Medical Research Services and Development Ltd., the technology transfer office of Hadassah Medical Center, announced today that they have entered into a research collaboration and licensing agreement for the identification of microbiome-based therapeutics that will enhance the response to and reduce adverse effects of anti-PD-1 and anti-PD-L1 in melanoma patients. The collaboration will combine Hadassah s knowhow and expertise in immunotherapy treatment of melanoma patients with MyBiotics proprietary microbiome technologies enabling development of novel therapeutics. The two-year joint research project will be conducted by researchers from MyBiotics together with a team of researchers at Hadassah Cancer Research Institute headed by Prof. Michal Lotem, MD., Head of the Center for Melanoma and Cancer Immunotherapy,